Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease

ACS Chem Neurosci. 2022 Jun 15;13(12):1697-1713. doi: 10.1021/acschemneuro.2c00172. Epub 2022 May 23.

Abstract

Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder featured by memory loss and cognitive default. However, there has been no effective therapeutic approach to prevent the development of AD and the available therapies are only to alleviate some symptoms with limited efficacy and severe side effects. Necroptosis is a new kind of cell death, being regarded as a genetically programmed and regulated pattern of necrosis. Increasing evidence reveals that necroptosis is tightly related to the occurrence and development of AD. This review aims to summarize the potential role of necroptosis in AD progression and the therapeutic capacity of targeting necroptosis for AD patients.

Keywords: Alzheimer’s disease; MLKL; RIPK1; RIPK3; necroptosis; therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Apoptosis
  • Humans
  • Necroptosis*
  • Necrosis
  • Protein Kinases / metabolism
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism

Substances

  • Protein Kinases
  • Receptor-Interacting Protein Serine-Threonine Kinases